Search
for
Sort by
Research 871–900 of 883
- Epidermal Stem Cells do not Communicate Through Gap Junctions
- Human Hair Follicle and Epidermal Melanocytes Exhibit Striking Differences in Their Aging Profile which Involves Catalase
- Delivery systems in nanocosmeceuticals
- A review of environmental and health effects of synthetic cosmetics
- Skin transcriptome reveals the periodic changes in genes underlying cashmere (ground hair) follicle transition in cashmere goats
- Epidemiology of Cosmetic Procedures: An Update for Dermatologists
- Treatment options and emotional well-being in patients with rosacea: An unsupervised machine learning analysis of over 200,000 posts
- Scanning electron microscopy of murine skin ultrathin sections and cultured keratinocytes
- Age-Induced Hair Graying and Oxidative Stress
- A Practical Guide to Hair Graft Placement Using the Sharp Implanter Method
- Oral Combination Treatment of Gefitinib (IressaTM) and Sasam-Kyeongokgo: Synergistic Effects on the NCI-H520 Tumor Cell Line
- From the Elephant Man to Barbie Girl: Dissecting the Freak from the Margins to the Mainstream
- Age-Induced Hair Graying and Oxidative Stress
- Eyelash alopecia areata: case series and literature review
- Characterization of scalp, eyelash and eyebrow hair regrowth in patients with severe alopecia areata randomized to placebo in brave AA1 and brave AA2 trials
- Latanoprost in the treatment of eyelash alopecia in alopecia areata universalis
- Isolated eyebrow and eyelash trichotillomania mimicking alopecia areata
- Development and validation of the Brigham Eyelash Tool for Alopecia (BELA): A measure of eyelash alopecia areata
- Concordance between clinician-reported and patient-reported outcomes of eyebrow and eyelash hair loss in patients with severe alopecia areata: Results from BRAVE-AA1 and BRAVE-AA2 studies
- Most men choose eyebrows versus scalp hair: Response to Mostaghimi et al., “Evaluation of eyebrow and eyelash regrowth and patient satisfaction in the phase 3 THRIVE-AA2 trial of deuruxolitinib in adult patients with alopecia areata”
- Bimatoprost in the treatment of eyelash universalis alopecia areata
- Instilled bimatoprost ophthalmic solution in patients with eyelash alopecia areata
- Population exposure–response analysis of the effect of ritlecitinib on eyebrow assessment and eyelash assessment in patients with alopecia areata
- 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study
- 42752 Evaluation of Eyebrow and Eyelash Regrowth and Patient Satisfaction in the Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- Lack of efficacy of topical latanoprost and bimatoprost ophthalmic solutions in promoting eyelash growth in patients with alopecia areata
- Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) Measures for Eyebrow, Eyelash and Nail Assessment in Alopecia Areata
- Lack of efficacy of topical latanoprost and bimatoprost ophthalmic solutions in promoting eyelash growth in patients with alopecia areata
- 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
- 42005 Sustained scalp, eyebrow, and eyelash hair regrowth with ritlecitinib through Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study